Novel biomarkers for hepatocellular carcinoma detection and treatment.
作者信息
Yi Hongyuan, Xu Haifeng
机构信息
Department of Hepatic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
出版信息
Hepatobiliary Surg Nutr. 2024 Oct 1;13(5):901-904. doi: 10.21037/hbsn-24-517. Epub 2024 Sep 26.
Abstract
摘要
相似文献
1
Novel biomarkers for hepatocellular carcinoma detection and treatment.用于肝细胞癌检测与治疗的新型生物标志物。
Hepatobiliary Surg Nutr. 2024 Oct 1;13(5):901-904. doi: 10.21037/hbsn-24-517. Epub 2024 Sep 26.
2
The potential of gut microbiome as a non-invasive predictive biomarker for early detection of pancreatic cancer and hepatocellular carcinoma.肠道微生物组作为一种非侵入性的预测性生物标志物，用于早期检测胰腺癌和肝细胞癌的潜力。
Eur Rev Med Pharmacol Sci. 2021 Dec;25(23):7275-7284. doi: 10.26355/eurrev_202112_27421.
3
Human microbiome is a diagnostic biomarker in hepatocellular carcinoma.人类微生物组是肝细胞癌的诊断生物标志物。
Hepatobiliary Pancreat Dis Int. 2020 Apr;19(2):109-115. doi: 10.1016/j.hbpd.2020.01.003. Epub 2020 Jan 30.
4
Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma.肠道微生物组分析作为一种针对早期肝细胞癌的靶向非侵入性生物标志物的工具。
Gut. 2019 Jun;68(6):1014-1023. doi: 10.1136/gutjnl-2017-315084. Epub 2018 Jul 25.
5
The Gut Microbiome as a Biomarker and Therapeutic Target in Hepatocellular Carcinoma.肠道微生物群作为肝细胞癌的生物标志物和治疗靶点
Cancers (Basel). 2023 Oct 7;15(19):4875. doi: 10.3390/cancers15194875.
6
Gut microbiome as a biomarker for predicting early recurrence of HBV-related hepatocellular carcinoma.肠道微生物组作为预测乙型肝炎病毒相关肝细胞癌早期复发的生物标志物。
Cancer Sci. 2023 Dec;114(12):4717-4731. doi: 10.1111/cas.15983. Epub 2023 Oct 1.
7
Research progress of gut microbiota in hepatocellular carcinoma.肠道微生物群在肝细胞癌中的研究进展。
J Clin Lab Anal. 2022 Jul;36(7):e24512. doi: 10.1002/jcla.24512. Epub 2022 Jun 19.
8
Discovering Biomarkers for Non-Alcoholic Steatohepatitis Patients with and without Hepatocellular Carcinoma Using Fecal Metaproteomics.利用粪便代谢组学发现伴有和不伴有肝细胞癌的非酒精性脂肪性肝炎患者的生物标志物。
Int J Mol Sci. 2022 Aug 9;23(16):8841. doi: 10.3390/ijms23168841.
9
The Gut Microbiome and Hepatocellular Carcinoma: Implications for Early Diagnostic Biomarkers and Novel Therapies.肠道微生物群与肝细胞癌：对早期诊断生物标志物和新疗法的影响。
Liver Cancer. 2021 Dec 21;11(2):113-125. doi: 10.1159/000521358. eCollection 2022 Apr.
10
Gut-microbiome Taxonomic Profiling as Non-invasive Biomarkers for the Early Detection of Alcoholic Hepatocellular Carcinoma.肠道微生物群分类分析作为酒精性肝细胞癌早期检测的非侵入性生物标志物
J Liver Cancer. 2020 Mar;20(1):32-40. doi: 10.17998/jlc.20.1.32. Epub 2020 Mar 31.
引用本文的文献
1
Immunotherapy targeting liver cancer tumor-initiating cells: challenges, mechanisms, and emerging therapeutic horizons.靶向肝癌肿瘤起始细胞的免疫疗法：挑战、机制及新兴治疗前景
Front Immunol. 2025 Jun 11;16:1621243. doi: 10.3389/fimmu.2025.1621243. eCollection 2025.
本文引用的文献
1
Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy.全球肝细胞癌流行病学趋势：对筛查、预防和治疗的启示。
Nat Rev Clin Oncol. 2023 Dec;20(12):864-884. doi: 10.1038/s41571-023-00825-3. Epub 2023 Oct 26.
2
A review of 2022 Chinese clinical guidelines on the management of hepatocellular carcinoma: updates and insights.《2022年中国肝细胞癌管理临床指南综述：更新与见解》
Hepatobiliary Surg Nutr. 2023 Apr 10;12(2):216-228. doi: 10.21037/hbsn-22-469. Epub 2023 Mar 2.
3
Gut microbiome evolution impacts the clinical outcomes of diseases.肠道微生物群的进化会影响疾病的临床结果。
Hepatobiliary Surg Nutr. 2023 Apr 10;12(2):261-263. doi: 10.21037/hbsn-23-127. Epub 2023 Mar 27.
4
A distinct microbiota signature precedes the clinical diagnosis of hepatocellular carcinoma.一种独特的微生物群特征先于肝细胞癌的临床诊断。
Gut Microbes. 2023 Jan-Dec;15(1):2201159. doi: 10.1080/19490976.2023.2201159.
5
The Microbiome and Liver Cancer.肠道微生物群与肝癌
Cancer J. 2023;29(2):57-60. doi: 10.1097/PPO.0000000000000646.
6
Alterations in gut microbiome and metabolomics in chronic hepatitis B infection-associated liver disease and their impact on peripheral immune response.慢性乙型肝炎感染相关肝病中肠道微生物组和代谢组学的改变及其对外周免疫反应的影响。
Gut Microbes. 2023 Jan-Dec;15(1):2155018. doi: 10.1080/19490976.2022.2155018.
7
The Intratumoral Bacterial Metataxonomic Signature of Hepatocellular Carcinoma.肝细胞癌的肿瘤内细菌分类群特征。
Microbiol Spectr. 2022 Oct 26;10(5):e0098322. doi: 10.1128/spectrum.00983-22. Epub 2022 Sep 29.
8
Periodontitis, chronic liver diseases, and the emerging oral-gut-liver axis.牙周炎、慢性肝病和新兴的口腔-肠道-肝脏轴。
Periodontol 2000. 2022 Jun;89(1):125-141. doi: 10.1111/prd.12427. Epub 2022 Mar 4.
9
Gut-liver axis-mediated mechanism of liver cancer: A special focus on the role of gut microbiota.肠-肝轴介导的肝癌发生机制：特别关注肠道微生物群的作用。
Cancer Sci. 2021 Nov;112(11):4433-4443. doi: 10.1111/cas.15142. Epub 2021 Sep 27.
10
Periodontal disease-related nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: An emerging concept of oral-liver axis.牙周病相关的非酒精性脂肪性肝病和非酒精性脂肪性肝炎：口腔-肝脏轴的一个新兴概念。
Periodontol 2000. 2021 Oct;87(1):204-240. doi: 10.1111/prd.12387.
Zotero 插件